Skip to main content

Thoracic Surgery Oncology Group 

In conjunction with the Fiona and Stanley Druckenmiller Center for Lung Cancer Research at Memorial Sloan Kettering Cancer Center and the AATS, the Thoracic Surgery Oncology Group (TSOG) was formed in 2017 to support a network of North American thoracic surgery clinical trials relevant to physicians and their patients—something that had been missing from the landscape in recent years. The overarching goal of the group is to improve the understanding of thoracic oncologic diseases and enhance patient care through the administration of multi-site trials focused on recent advances in precision medicine, immunotherapy, and intraoperative imaging. TSOG will actively accrue patients to relevant investigator-initiated clinical trials, as well as select industry-sponsored clinical trials, designed to improve outcomes for patients with thoracic malignancies. 

Committee Members

David R. Jones, MD - Chair 
Raphael Bueno, MD - Member 
David H. Harpole, MD - Member  
Ara A. Vaporciyan, MD - Member 

Sites 

  • Brigham and Women’s Hospital
  • Duke University
  • Mayo Clinic
  • The University of Texas MD Anderson Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • Centre Hospitalier de l’Université de Montréal 
  • University of Pittsburgh
  • University of Toronto 
  • Washington University in St. Louis

Principal Investigators

 

James M. Isbell, MD, MSCI
Memorial Sloan Kettering Cancer Center

“Study to evaluate perioperative circulating tumor DNA as prognostic biomarker in patients undergoing neoadjuvant therapy for resectable non-small cell lung cancer.” —TSOG 101

The aim of this study is to determine the validity of using quantitative ctDNA as a surrogate marker for pathologic treatment response in patients receiving neoadjuvant therapy for stage IIA-IIIB NSCLC who are undergoing curative-intent resection.

The second aim is to determine, in patients with NSCLC, the prognostic value of persistent ctDNA following curative-intent resection for predicting recurrence, disease-free survival, and overall survival.

The third aim is to correlate the percent change in levels of ctDNA to percent change in the SUVmax of the primary tumor on 18-FDG-PET scan before and after neoadjuvant therapy.

 

 

James Huang, MD
Memorial Sloan Kettering Cancer Center

“Registry trial of active surveillance for multifocal ground glass opacities (GGOs).” —TSOG 102

The primary objective of this study is to determine lung cancer–specific survival at 5 years among patients undergoing active surveillance for GGOs.

The secondary objective is to determine the following endpoints among patients undergoing active surveillance for GGOs: overall survival, freedom from progression (any), freedom from nodal progression, freedom from distant progression, cumulative incidence of intervention (biopsy or resection), cumulative incidence of a new GGO, and cumulative incidence of confirmed lung cancer diagnosis.

 

 

Mara Antonoff, MD
The University of Texas MD Anderson Cancer Center

 

“The role of multimodality management in risk-stratified patients with lung-limited metastatic colorectal cancer.” —TSOG 103

The primary objectives of this study are to compare recurrence-free survival in patients with “low-risk” lung-limited mCRC undergoing pulmonary metastasectomy with or without perioperative chemotherapy, as well as to compare overall survival in patients with “high-risk” lung-limited mCRC receiving systemic chemotherapy with or without surgical resection.

Additional exploratory objectives involve the evaluation of changes in ctDNA following surgical resection and/or systemic chemotherapy in patients with lung-limited mCRC.

 

For additional details about TSOG and how to get involved, please contact Project Coordinator Maria Singh at singhm1@mskcc.org: